Search research articles
Contact Us
Filters
Showing results (51-60 of 79) with videos related to
Page
of 8
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
October 8, 2014
Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions
Julia Hentschel, Nele Fischer, Wibke K Janhsen, et al.
Rhinology
|
September 13, 2015
Reduced effect of intravenous antibiotic treatment on sinonasal markers in pulmonary inflammation
Franziska Doht, Julia Hentschel, Nele Fischer, et al.
Plos One
|
August 1, 2012
Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores
Thomas Karlas, Marie Neuschulz, Annett Oltmanns, et al.
Jornal De Pediatria
|
August 12, 2024
Cross-cultural adaptation and validation of the CFAbd-Score for gastrointestinal symptoms in patients with cystic fibrosis
Flávia N S Infante, Elizete A Lomazi, Carlos Zagoya, et al.
BMJ Open Respiratory Research
|
May 3, 2024
Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis receiving CFTR modulator therapy
Pierre-Régis Burgel, Manfred Ballmann, Pavel Drevinek, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 13, 2025
The novel CFAbd-Score.kid<sup>Ⓒ</sup> reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor - first results
Jochen G Mainz, Pauline Sadrieh, Lilith Bechinger, et al.
Plos One
|
May 5, 2017
Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings
Harold Tabori, Christin Arnold, Anke Jaudszus, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 17, 2015
Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor
Simon Y Graeber, Martin J Hug, Olaf Sommerburg, et al.
Drug Design, Development and Therapy
|
March 6, 2014
Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study
Jochen G Mainz, Katja Schädlich, Claudia Schien, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
October 8, 2023
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study
Jochen G Mainz, Karen Lester, Basil Elnazir, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 79) with videos related to
Sort By:
Page
of 8
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
October 8, 2014
Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions
Julia Hentschel, Nele Fischer, Wibke K Janhsen, et al.
Rhinology
|
September 13, 2015
Reduced effect of intravenous antibiotic treatment on sinonasal markers in pulmonary inflammation
Franziska Doht, Julia Hentschel, Nele Fischer, et al.
Plos One
|
August 1, 2012
Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores
Thomas Karlas, Marie Neuschulz, Annett Oltmanns, et al.
Jornal De Pediatria
|
August 12, 2024
Cross-cultural adaptation and validation of the CFAbd-Score for gastrointestinal symptoms in patients with cystic fibrosis
Flávia N S Infante, Elizete A Lomazi, Carlos Zagoya, et al.
BMJ Open Respiratory Research
|
May 3, 2024
Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis receiving CFTR modulator therapy
Pierre-Régis Burgel, Manfred Ballmann, Pavel Drevinek, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
September 13, 2025
The novel CFAbd-Score.kid<sup>Ⓒ</sup> reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor - first results
Jochen G Mainz, Pauline Sadrieh, Lilith Bechinger, et al.
Plos One
|
May 5, 2017
Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings
Harold Tabori, Christin Arnold, Anke Jaudszus, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 17, 2015
Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor
Simon Y Graeber, Martin J Hug, Olaf Sommerburg, et al.
Drug Design, Development and Therapy
|
March 6, 2014
Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study
Jochen G Mainz, Katja Schädlich, Claudia Schien, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
October 8, 2023
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years - The RECOVER study
Jochen G Mainz, Karen Lester, Basil Elnazir, et al.
Page
of 8